Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 -
EBIT 2017 -54,3 M
Net income 2017 -63,1 M
Debt 2017 -
Yield 2017 -
Sales 2018 12,7 M
EBIT 2018 -60,3 M
Net income 2018 -64,7 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 2,59x
Capitalization 32,8 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on developing and commercializing products to treat treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic... 
More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating :
More Ratings
Latest news on ANTA PHAR
03/20 ANTH The Law Offices of Vincent Wong Reminds Investors of a Class Action Invo..
03/16 ANTHERA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
03/16 ANTHERA PHARMACEUTICALS,INC. (NASDAQ : ANTH) Files An 8-K Entry into a Material ..
03/16 ANTHERA PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Other ..
03/15 ANTHERA PHARMACEUTICALS : Announces Pricing of $15.0 Million Public Offering of ..
03/14 Anthera Pharmaceuticals Announces Pricing of $15.0 Million Public Offering of..
03/14 ANTHERA PHARMACEUTICALS : Announces Proposed Public Offering of Common Stock and..
03/13 Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock an..
03/02 ROBBINS ARROYO LLP : Anthera Pharmaceuticals, Inc. ANTH Misled Shareholders Acco..
03/01 Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 Fr..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 5
Average target price 1,34 $
Spread / Average Target 228%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John Craig Thompson President, Chief Executive Officer & Director
Paul F. Truex Executive Chairman
May Liu CAO, Senior VP-Finance & Administration
Charles V. Olson Chief Technology Officer
William R. Shanahan Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR33
AMGEN, INC.14.53%123 319
CELGENE CORPORATION6.58%95 978
GILEAD SCIENCES, INC.-5.28%88 658
REGENERON PHARMACEUTIC..0.56%39 159
ACTELION LTD24.49%29 874
More Results